Observational studyClinical rheumatology2026
After the earthquake: clinical observations in axial spondyloarthritis patients receiving biologic therapy.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the medium- and long-term effects of a major earthquake epicenter in Kahramanmaras, Turkey, on Axial Spondyloarthritis (axSpA) patients receiving biological therapy in the affected region. PATIENTS AND
methodsA single-center retrospective observational study included 159 patients with axSpA receiving biologic therapy who applied to our outpatient rheumatology department between February 2023 and October 2024. Clinical, laboratory and disease-related parameters pre- and post-earthquake were retrieved from the hospital database.
resultsThe median age of patients with axSpA was 41 (IQR:14) (female 43, male 40) years, 73.6% were male, and the disease duration was 8 (IQR:7) years. The median follow-up duration for patients in the post-earthquake period was 16 months. Fifty-five patients (34.6%) had discontinued their treatment due to the earthquake and remained without treatment for a median of 75 (IQR:58) days. When patients who discontinued treatment were compared with those who continued, the mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores after the earthquake were 5.6 and 3.3, respectively, and the difference was statistically significant (p = 0.01). The duration of treatment discontinuation showed a significant positive correlation with post-earthquake BASDAI scores (r = 0.603, p = 0.01). When evaluating the effect of treatment discontinuation duration on clinical outcomes, a longer duration of treatment discontinuation was significantly associated with increased disease activation (p = 0.001) and treatment non-response (p = 0.013).
conclusionThis study, highlights the significant impact of treatment discontinuation on disease activity and response in patients with axSpA receiving biologic therapy. AxSpA inherently presents complex challenges in monitoring and treatment, which are exacerbated in disaster settings. Therefore, there is a need for disaster action plans that incorporate a multidisciplinary approach adapted to the management of chronic rheumatic diseases such as axSpA. Key points • Disease control in axSpA patients is critical to prevent complications. • Disasters like earthquakes are difficult to manage chronic diseases such as axSpA. • Emergency action plans need to be established to ensure the effective management of axSpA patients during disaster situations.
Indexed as
Identifiers
41212369What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.